BUZZ-Citi initiates Apogee with "buy" rating on potential for eczema drug

Reuters2025-03-13
BUZZ-Citi initiates Apogee with "buy" rating on potential for eczema drug

** Brokerage Citi starts coverage on Apogee Therapeutics APGE.O with "buy" rating

** Brokerage sets PT at $95, representing more than double upside to the stock's last close

** Brokerage sees peak combined adjusted revenues of $2.2 billion from co's experimental drug candidate APG777 to treat atopic dermatitis (AD) or often called as eczema, a type of skin disease, and asthma

** Citi says "capturing a fraction of the Dupixent patient in AD is itself a multi-billion dollar opportunity"

** Dupixent is jointly developed by Sanofi SASY.PA and Regeneron REGN.O for patients with AD and asthma

** Brokerage believes physicians are unlikely to switch well-managed patients from Dupixent to APG777 unless the latter shows comparable or superior efficacy with similar safety profile

** All eight brokerages covering the stock rate it at "buy" or higher, their median PT is $93.5

** APGE has fallen 44.4% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment